OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a report issued on Friday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

OPGN opened at $4.17 on Friday. The firm’s fifty day moving average is $2.41 and its 200 day moving average is $1.72. OpGen has a fifty-two week low of $0.53 and a fifty-two week high of $6.30.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.